Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 178

1.

GPR30 and estrogen receptor expression: new insights into hormone dependence of inflammatory breast cancer.

Arias-Pulido H, Royce M, Gong Y, Joste N, Lomo L, Lee SJ, Chaher N, Verschraegen C, Lara J, Prossnitz ER, Cristofanilli M.

Breast Cancer Res Treat. 2010 Aug;123(1):51-8. doi: 10.1007/s10549-009-0631-7. Epub 2009 Nov 10.

2.

Distribution of GPR30, a seven membrane-spanning estrogen receptor, in primary breast cancer and its association with clinicopathologic determinants of tumor progression.

Filardo EJ, Graeber CT, Quinn JA, Resnick MB, Giri D, DeLellis RA, Steinhoff MM, Sabo E.

Clin Cancer Res. 2006 Nov 1;12(21):6359-66.

3.

Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.

Arpino G, Weiss H, Lee AV, Schiff R, De Placido S, Osborne CK, Elledge RM.

J Natl Cancer Inst. 2005 Sep 7;97(17):1254-61.

4.

Immunophenotypic analysis of inflammatory breast cancers: identification of an 'inflammatory signature'.

Charafe-Jauffret E, Tarpin C, Bardou VJ, Bertucci F, Ginestier C, Braud AC, Puig B, Geneix J, Hassoun J, Birnbaum D, Jacquemier J, Viens P.

J Pathol. 2004 Mar;202(3):265-73.

PMID:
14991891
5.

Triple-negative subtype predicts poor overall survival and high locoregional relapse in inflammatory breast cancer.

Li J, Gonzalez-Angulo AM, Allen PK, Yu TK, Woodward WA, Ueno NT, Lucci A, Krishnamurthy S, Gong Y, Bondy ML, Yang W, Willey JS, Cristofanilli M, Valero V, Buchholz TA.

Oncologist. 2011;16(12):1675-83. doi: 10.1634/theoncologist.2011-0196. Epub 2011 Dec 6.

6.
7.

Lack of G protein-coupled estrogen receptor (GPER) in the plasma membrane is associated with excellent long-term prognosis in breast cancer.

Sjöström M, Hartman L, Grabau D, Fornander T, Malmström P, Nordenskjöld B, Sgroi DC, Skoog L, Stål O, Leeb-Lundberg LM, Fernö M.

Breast Cancer Res Treat. 2014 May;145(1):61-71. doi: 10.1007/s10549-014-2936-4. Epub 2014 Apr 9.

PMID:
24715381
8.
9.

Epidermal growth factor receptor and vascular endothelial growth factor receptor 2 are specific biomarkers in triple-negative breast cancer. Results from a controlled randomized trial with long-term follow-up.

Rydén L, Jirström K, Haglund M, Stål O, Fernö M.

Breast Cancer Res Treat. 2010 Apr;120(2):491-8. doi: 10.1007/s10549-010-0758-6. Epub 2010 Feb 5.

PMID:
20135347
10.

Quantitative ER and PgR assessment as predictors of benefit from lapatinib in postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer.

Finn RS, Press MF, Dering J, O'Rourke L, Florance A, Ellis C, Martin AM, Johnston S.

Clin Cancer Res. 2014 Feb 1;20(3):736-43. doi: 10.1158/1078-0432.CCR-13-1260. Epub 2013 Nov 6.

11.

Discordances in estrogen receptor status, progesterone receptor status, and HER2 status between primary breast cancer and metastasis.

Curtit E, Nerich V, Mansi L, Chaigneau L, Cals L, Villanueva C, Bazan F, Montcuquet P, Meneveau N, Perrin S, Algros MP, Pivot X.

Oncologist. 2013 Jun;18(6):667-74. doi: 10.1634/theoncologist.2012-0350. Epub 2013 May 30.

12.

The interactions between GPR30 and the major biomarkers in infiltrating ductal carcinoma of the breast in an Asian population.

Kuo WH, Chang LY, Liu DL, Hwa HL, Lin JJ, Lee PH, Chen CN, Lien HC, Yuan RH, Shun CT, Chang KJ, Hsieh FJ.

Taiwan J Obstet Gynecol. 2007 Jun;46(2):135-45. Erratum in: Taiwan J Obstet Gynecol. 2007 Sep;46(3):320-1.

13.

[Prognostic value of estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in node positive breast cancer patients treated by mastectomy].

Wang SL, Li YX, Song YW, Wang WH, Jin J, Liu YP, Liu XF, Yu ZH.

Zhonghua Zhong Liu Za Zhi. 2010 Jul;32(7):520-5. Chinese.

PMID:
21029696
15.

Triple-negative breast cancer with brain metastases: a comparison between basal-like and non-basal-like biological subtypes.

Niwińska A, Olszewski W, Murawska M, Pogoda K.

J Neurooncol. 2011 Dec;105(3):547-53. doi: 10.1007/s11060-011-0616-3. Epub 2011 Jun 9.

16.

Prognostic significance of estrogen receptor, progesterone receptor, HER2/neu, Ki-67, and nm23 expression in patients with invasive breast cancer.

Cubukcu E, Kanat O, Fatih Olmez O, Kabul S, Canhoroz M, Avci N, Deligonul A, Hartavi M, Cubukcu S, Olmez F, Kurt E, Evrensel T, Gokgoz S, Manavoglu O.

J BUON. 2013 Apr-Jun;18(2):359-65.

PMID:
23818346
17.

Lower level of MAPK expression is associated with anthracycline resistance and decreased survival in patients with hormone receptor negative breast cancer.

Derin D, Eralp Y, Ozluk Y, Yavuz E, Guney N, Saip P, Igci A, Ozmen V, Kücücük S, Aslay I, Aydiner A, Topuz E.

Cancer Invest. 2008 Aug;26(7):671-9. doi: 10.1080/07357900801891628.

PMID:
18608215
18.

Molecular subtype approximated by quantitative estrogen receptor, progesterone receptor and Her2 can predict the prognosis of breast cancer.

Chen XS, Ma CD, Wu JY, Yang WT, Lu HF, Wu J, Lu JS, Shao ZM, Shen ZZ, Shen KW.

Tumori. 2010 Jan-Feb;96(1):103-10.

19.

Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy.

Darb-Esfahani S, Loibl S, Müller BM, Roller M, Denkert C, Komor M, Schlüns K, Blohmer JU, Budczies J, Gerber B, Noske A, du Bois A, Weichert W, Jackisch C, Dietel M, Richter K, Kaufmann M, von Minckwitz G.

Breast Cancer Res. 2009;11(5):R69. doi: 10.1186/bcr2363. Epub .

20.

Prognostic relevance of carcinoembryonic antigen and estrogen receptor status in breast cancer patients.

Esteban JM, Felder B, Ahn C, Simpson JF, Battifora H, Shively JE.

Cancer. 1994 Sep 1;74(5):1575-83.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk